Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Date:7/30/2009

---- ---- ---- ---- Operating expenses Research and development $4,648 $5,501 $11,524 $11,510 General and administrative 2,532 1,975 4,587 4,020 ----- ----- ----- ----- Total operating expenses(1) 7,180 7,476 16,111 15,530 Interest income and other, net 210 384 381 995 Gain from valuation of common stock warrant liability 440 - 440 - --- --- --- --- Total other income, net 650 384 821 995 Net loss(1) $(6,530) $(7,092) $(15,290) $(14,535) ======= ======= ======== ======== Net loss per share, basic and diluted(1) $(0.21) $(0.25) $(0.51) $(0.51) ====== ====== ====== ====== Shares used in calculating net loss per share, basic and diluted 31,493 28,731 30,173 28,714 ====== ====== ====== ====== (1) Includes non-cash operating expenses of $1,062 and $668 determined in accordance with Statement of Financial Accounts Standards No. 123(R), "Share-Based Payment" (SFAS No. 123(R)) or approximately $0.03 and $0.02 effect on basic and diluted net loss per common share for the three months ended June 30, 2009 and 2008, respectively. Research and development expense and general and administrative expense includes $616 and $446, respectively, of non-cash operating expenses determined in accordance with SFAS No. 123(R) for the three months ended June 30, 2009. Includes non-cash operating expenses of $1,746 and $1,329 determined in
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
2. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
3. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
5. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
6. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
7. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
8. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
9. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
11. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... the detection of foodborne pathogens, today announced that Paul ... Company Emerging Growth Conference on September 2 at 9:20am ... York Marriott Marquis. A live webcast ... relations section of Roka Bioscience,s website at http://rokabio.investorroom.com/ ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... Inc. today announced the,scheduled presentation of data from ... long-acting human growth hormone (hGH) analogue developed in,collaboration ... meeting in Rio de Janeiro. Andrew R. Hoffman, ... Affairs at Stanford University,will present the clinical results ...
... Incorporated (Nasdaq:,VICL) today reported financial results for the quarter ended ... $0.8 million, compared,with revenues of $0.4 million for the third ... 2008 was $9.8 million or $0.24 per share, compared,with $9.2 ... 2007., Revenues for the first nine months of 2008 ...
... - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or ... the three and nine-month periods ended September ... Oncolytics made a decision in early November ... using the combination of REOLYSIN(R) with,paclitaxel/carboplatin in ...
Cached Biology Technology:Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Third Quarter Results 9
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... University and the University of Missouri are developing a ... useful byproducts at a cost of less than a ... the technological aspects of the project, the researchers are ... developing countries, since many areas with the greatest sanitation ...
... flu strain that emerged in China earlier this year has ... be reassured by this apparent lull in infections. The virus ... of a pathogen that may yet lead to a pandemic, ... and Infectious Diseases. David Morens, Jeffery Taubenberger, and Anthony Fauci, ...
... Boston As the population gets older, and the baby ... assume that the number of trips to the emergency department ... Brigham and Women,s Hospital (BWH), which shows that population aging ... to increase between now and 2050. However, visits will become ...
Cached Biology News:Pressure cooker on steroids treats human waste 2Pressure cooker on steroids treats human waste 3H7N9 influenza: History of similar viruses gives cause for concern 2H7N9 influenza: History of similar viruses gives cause for concern 3The aging population and emergency departments 2
... expression vectors, we in-troduced a new concept, namely ... tran-scriptional level at the T7 phage promoter, and ... the plasmid copy number, The main advantage of ... practically all of the outstanding features of the ...
Mouse monoclonal [34B12] to Nop5p + Nop58p - Nucleolar Marker ( Abpromise for all tested applications)....
... the ultimate tool for investigating dynamic events ... previously have been limited at wavelengths longer ... not transmit in the deep UV. HORIBA ... introduces a filter-based confocal system (the DynaMic) ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
Biology Products: